Ryo C Yanagita Selected Research

Isoenzymes

11/2023	Biological evaluation of a phosphate ester prodrug of 10-methyl-aplog-1, a simplified analog of aplysiatoxin, as a possible latency-reversing agent for HIV reactivation.
11/2022	A simplified analog of debromoaplysiatoxin lacking the B-ring of spiroketal moiety retains protein kinase C-binding and antiproliferative activities.
6/2022	AI and computational chemistry-accelerated development of an alotaketal analogue with conventional PKC selectivity.
1/2021	Effects of side chain length of 10-methyl-aplog-1, a simplified analog of debromoaplysiatoxin, on PKC binding, anti-proliferative, and pro-inflammatory activities.
1/2016	Binding mode prediction of aplysiatoxin, a potent agonist of protein kinase C, through molecular simulation and structure-activity study on simplified analogs of the receptor-recognition domain.
4/2014	Synthesis and biological activities of simplified analogs of the natural PKC ligands, bryostatin-1 and aplysiatoxin.
8/2013	Effects of the methoxy group in the side chain of debromoaplysiatoxin on its tumor-promoting and anti-proliferative activities.
5/2012	Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ.
10/2010	Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
1/2008	Synthesis, conformational analysis, and biological evaluation of 1-hexylindolactam-V10 as a selective activator for novel protein kinase C isozymes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryo C Yanagita Research Topics

Disease

22	Neoplasms (Cancer) 11/2023 - 01/2008
9	Alzheimer Disease (Alzheimer's Disease) 06/2022 - 01/2008
3	Acquired Immunodeficiency Syndrome (AIDS) 04/2014 - 06/2009
2	HIV Infections (HIV Infection) 06/2022 - 06/2009
1	Adenocarcinoma 09/2022
1	Uterine Diseases (Endometrial Disease) 09/2022
1	Obesity 01/2014
1	Leukemia 01/2014
1	Reperfusion Injury 01/2008

Drug/Important Bio-Agent (IBA)

12	Protein Kinase CIBA 11/2023 - 06/2009
10	IsoenzymesIBA 11/2023 - 01/2008
9	aplysiatoxinIBA 11/2023 - 06/2009
5	debromoaplysiatoxinIBA 01/2021 - 06/2012
3	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2022
3	alloseIBA 01/2020 - 01/2014
3	CarcinogensIBA 08/2013 - 06/2009
3	BryostatinsIBA 06/2012 - 06/2009
2	AntibodiesIBA 01/2022 - 04/2020
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2022
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2020
2	MonosaccharidesIBA 01/2020 - 01/2020
2	Hydroxyl RadicalIBA 04/2017 - 10/2010
2	Epstein-Barr virus early antigenIBA 05/2013 - 01/2012
2	bryostatin 1IBA 05/2012 - 06/2009
2	Phorbol EstersIBA 01/2011 - 06/2009
2	Protein Kinases (Protein Kinase)IBA 01/2011 - 10/2010
1	spiroketalIBA 11/2022
1	GelsIBA 09/2022
1	CollagenIBA 09/2022
1	Collagen Type I (Type I Collagen)IBA 09/2022
1	carvoneIBA 07/2022
1	idoseIBA 01/2020
1	LipidsIBA 01/2014
1	SaponinsIBA 01/2014
1	echinoside AIBA 01/2014
1	TriterpenesIBA 01/2014
1	Dietary Fats (Dietary Fat)IBA 01/2014
1	holothurin AIBA 01/2014
1	BromineIBA 05/2013
1	IodineIBA 05/2013
1	LigandsIBA 06/2012
1	lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA 06/2012
1	prostratinIBA 06/2009
1	Therapeutic UsesIBA 06/2009
1	Antineoplastic Agents (Antineoplastics)IBA 06/2009
1	1-hexylindolactam-V10IBA 01/2008

Therapy/Procedure

3	Therapeutics 09/2022 - 05/2012